Clinical Trial Update: Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial from Maastricht University Medical Center will evaluate boosting osimertinib exposure with cobicistat to improve drug exposure and asse…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cobicistat (cobicistat)
• Osimertinib (osimertinib)

Snippet

Sponsor: Maastricht University Medical Center | Conditions: Non-small Cell Lung Cancer | Phase 4 | Status: RECRUITING